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Manuel Aguilar-Diosdado1,2, Ángela M. Valverde3,7 and Ana I. Arroba1,2*
1 Research Unit, Instituto de Investigación e Innovación en Ciencias Biomédicas de la Provincia de Cádiz (INiBICA), Hospital
Universitario Puerta del Mar, Cádiz, Spain, 2 Department of Endocrinology and Metabolism, University Hospital Puerta del
Mar, Cádiz, Spain, 3 Department of Metabolism and Cell Signaling, Instituto de Investigaciones Biomédicas Alberto Sols
(IIBm) (CSIC/UAM), Madrid, Spain, 4 Departamento de Quı́mica Orgánica, Facultad de Quı́mica, Universidad de Sevilla,
Sevilla, Spain, 5 Instituto de Investigaciones Quı́micas (IIQ), CSIC - Universidad de Sevilla, Sevilla, Spain, 6 Área Genética,
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Diabetic retinopathy (DR) is one of the most common complications of Diabetes Mellitus
(DM) and is directly associated with inflammatory processes. Currently, neuro-
inflammation is considered an early event in DR and proceeds via microglia polarization.
A hallmark of DR is the presence of retinal reactive gliosis. Here we report the beneficial
effect of (SS,1R)-1-docecylsulfiny-5N,6O-oxomethylidenenojirimycin ((Ss)-DS-ONJ), a
member of the sp2-iminosugar glycolipid (sp2-IGL) family, by decreasing iNOS and
inflammasome activation in Bv.2 microglial cells exposed to pro-inflammatory stimuli.
Moreover, pretreatment with (Ss)-DS-ONJ increased Heme-oxygenase (HO)-1 as well as
interleukin 10 (IL10) expression in LPS-stimulated microglial cells, thereby promoting M2
(anti-inflammatory) response by the induction of Arginase-1. The results strongly suggest
that this is the likely molecular mechanism involved in the anti-inflammatory effects of (SS)-
DS-ONJ in microglia. (SS)-DS-ONJ further reduced gliosis in retinal explants from type 1
diabetic BB rats, which is consistent with the enhanced M2 response. In conclusion,
targeting microglia polarization dynamics in M2 status by compounds with anti-
inflammatory activities offers promising therapeutic interventions at early stages of DR.
Keywords: sp2-iminosugar glycolipids, diabetic retinopathy, microglia, immunomodulation, M2 responseINTRODUCTION
Most patients with diabetes mellitus (DM) will develop some grade of diabetic retinopathy (DR) (1). The
incidence of DR is growing and will increase several fold in the coming decades. It is the main cause of
visual failure in the working-age population (2). DR is consider a common microvascular complication
of DM, and it generally involves microvascular complications of capillary endothelium and pericytesorg March 2021 | Volume 12 | Article 6321321
Cano-Cano et al. A M2-Response Induction Delay DR Progressionleading to micro-aneurysm, blood retinal barrier (BRB) leakage and
fragile new blood vessel formation (neovascularization) (3).
Nevertheless, retinal neurodegeneration is present before to
clinically-overt microvascular disturbances, and recent evidences
suggest that neurodegeneration collaborates on the development of
microvascular dysfunction and neovascularization (4). Several
agents with neuroprotective actions are, therefore, being studied
as potential therapeutics against DR (5).
Retinal inflammation is an early stage in DR, and plays a crucial
role in its development (6). As occurs in other neurodegenerative
diseases, DR displays an inflammatory component associated with
alterations in the retina tissue. Inflammation released by increased
glycolytic metabolites has been well characterized in patients with
DR, and retinal inflammation contributes to vascular
permeabilization and disruption of the BRB (7). Inflammation
and apoptosis are important pathological processes of DR that
often lead to necrosis of retinal cells (8). Consequently, compounds
with inflammation and apoptosis regulatory capabilities have strong
potential for the treatment of DR. In this context, we have
previously observed that some sulfur-linked sp2-iminosugar
glycolipids (sp2-IGLs), such as (1R)-1-dodecylsulfonyl-5N,6O-
oxomethylidenenojirimycin (DSO2-ONJ) (Figure 1), efficiently
promoted microglia polarization from the pro-inflammatory (M1)
towards the anti-inflammatory (M2) state. Biochemical and
computational data support a mechanism involving non-
canonical auto-phosphorylation of p38a mitogen-activated
protein kinase (MAPK), a key player in the inflammatory
cascade, via binding of the sp2-IGL to the lipid binding site of the
protein (6, 9). Contrary to other immuno-regulatory glycolipids,
the sp2-IGLs are metabolically stable and can be prepared in the
laboratory in pure anomeric form with total stereo-selectivity,
thereby providing a suitable platform for glyco-drug design (10–16).
Available data on the biological activity of the sp2-IGLs reveal
that the nature of the glycosidic group bridging the sugar-like
glycone moiety (sp2-iminosugar) (17, 18) and the lipid aglycone
plays a critical role in the anti-inflammatory potential, probably by
favorably orienting the sp2-IGLmolecule in the lipid binding pocket
of p38a MAPK. Given the outstanding results obtained for DSO2-
ONJ (9), replacing the sulfone tether by a closely-related quasi-
isosteric functionality, e.g. a chiral sulfoxide group, seemed very
promising in the search for new candidates for DR treatment. As a
proof of concept, we have studied the effect of (SS,1R)-1-
dodecylsulfinyl-5N,6O-oxomethylidenenojirimycin (referred to as
(SS)-DS-ONJ, Figure 1) in Bv.2 microglial cells and retinal explants
of type 1 diabetic BB rats within the environment of inflammation
and immune modulation associated with DR. The data support the
idea that (SS)-DS-ONJ induces of IL10 production and enhances of
the action of arginase-1 in theM2 response, which is associated with
inhibition of the inflammasome complex.METHODS
Reagents
Fetal bovine serum (FBS) and culture media were obtained from
Invitrogen (Grand Island, NY, USA). Bovine serum albuminFrontiers in Immunology | www.frontiersin.org 2(BSA), MTT, crystal violet, glutaraldehyde, N-(1-naphthyl)
ethylenediamine (NEDA), sulfanilamide and bacterial
lipopolysaccharide (LPS) were purchased from Sigma-Aldrich
(St Louis, MO, USA). IL4 and IL13 were purchased from
Preprotech (London, UK). Acrylamide, immunoblot PVDF
membranes were purchased from Bio-Rad (Madrid, Spain).
BCA reagent and chemiluminescent HRP substrate were
purchased from Pierce (Rockford, IL, USA).
Antibodies
Antibodies against IkBa (sc-371), JNK (sc-571), p65-NFkB
(p65) (sc-732) and phospho-p38a MAPK (Thr 180/Tyr182)
(sc-17852-R) were purchased from Santa Cruz Biotechnology
(Palo Alto, CA, USA). Anti-phospho JNK (Thr183/Tyr185)
(#4668) and anti-p38a MAPK (#9212) antibodies were
purchased from Cell Signaling Technology (Danvers, MA,
USA). Anti-caspase-1 (p10) (ab 179515), iNOS (ab 15323),
HO-1 (ab 137749), antibodies were purchased from Abcam
(Cambridge, UK). Anti-Arginase-1 (BD610708) antibody was
purchased from BD Bioscience (Madrid, Spain). Anti-Glial
Fibrillary Acidic Protein (GFAP) antibody (Z0334) was
obtained from DAKO (Glostrup, Denmark). Anti-NLRP3
(AG-20B-0006) was purchased from AdipoGen Life Science
(Liestal, Switzerland) and anti-a-tubulin (T-5168) antibody
was from Sigma-Aldrich (St Louis, MO, USA).
Synthesis of the sp2-Iminosugar Glycolipid
(SS)-DS-ONJ
(SS1R)-1-Dodecylsulfinyl-5N,6O-oxomethylidenenojirimycin
(referred to as (SS)-DS-ONJ) was synthesized by controlled
o x i d a t i o n o f ( 1 R ) - 1 - d o d e c y l t h i o - 5 N , 6 O -
oxomethylidenenojirimycin with m-chloroperbenzoic acid and
subsequent column chromatography separation from the
corresponding (SR)-diastereomer (SR)-DS-ONJ (Figure 1A),
following the procedure previously reported (16).
Cell Culture
Murine microglia Bv.2 cell line was generously provided by Dr.
M. L. Nieto (IBGM, Spain) and previously has been published
[6,9,14]. Bv.2 cells were cultured at 37°C in a humidified
atmosphere with 5% CO2 in RPMI supplemented with 10%
(v/v) heat inactivated FBS, 1% (v/v) penicillin/streptomycin
(Sigma) and 2 mM L-glutamine (Gibco, Carlsbad, California,
USA). Bv.2 cells were grown to 70% confluence and then washed
twice with PBS. The cells were further cultured in serum-free
medium and subsequently stimulated with LPS (200 ng/mL)
in the presence or absence of (SS)-DS-ONJ (1, 10, 50 mM) for
24h in cell survival and Griess test approaches. In further
experiments, Bv.2 were pre-incubated with (SS)-DS-ONJ at 10
mM or a mixture of IL4/IL13 (10ng/mL each; a M2 response
inductors) for 4 h before the addition of LPS (200 ng/mL) for a
further 24 h.
Retinal Explants
All animal procedures were performed with the approval of the
Cádiz University School of Medicine (Cádiz, Spain) CommitteeMarch 2021 | Volume 12 | Article 632132
Cano-Cano et al. A M2-Response Induction Delay DR Progressionfor the Ethical Use and Care of Experimental Animals. Animal
experimentation conducted in this study followed the
recommendations of the Federation of European Laboratory
Animal Science Associations (FELASA) on health monitoring
in accordance with the regulations of the Association for
Research in Vision and Ophthalmology (ARVO).
Bio-Breeding (BB) and Wistar rats were maintained under
conventional conditions in an environment-controlled room
(20-21°C, 12 h light-dark cycle) with water and standard
laboratory rat chow available ad libitum. Blood samples from
the tail vein was used in BB rats for weekly random glucose
measurements using an automatic glucose monitor (Freestyle
Optium Neo, Abbott, Madrid, Spain). Diabetes onset was defined
by glucose levels above 270 mg/dL (14.98 mmol/L). In vivo assays
were performed with retinas from 6-week-old male or female
Wistar and BB rats. The rats were euthanized by an overdose of
anesthesia, and the eyes were enucleated. The lens, anterior
segment, vitreous body, retinal pigment epithelium and sclera
were removed. The retinas were immediately frozen for protein
extraction. The animals were sacrificed at 4, 5 or 6 weeks of age
according to the experimental approach.
Ex vivo assays were performed with retinas from 6-week-old
male or female BB rats. The retinas from BB rats were cultured in
R16 medium (provided by Dr. P.A. Ekstrom, Lund University,
Sweden) with no additional serum. Retinas were cultured with
(SS)-DS-ONJ at 20 mM as indicated in the figure legends.Frontiers in Immunology | www.frontiersin.org 3Analysis of the Cellular Viability by Crystal
Violet Staining and MTT Assay
After cell treatments for 24 h, the medium was discarded and the
remaining viable adherent cells were fixed with 10%
glutaraldehyde and stained with crystal violet (0.1% w/v in
water) for 20 min. The plates were then rinsed with tap water
and allowed to dry. Acetic acid (10%) was added to solubilize the
crystal violet. The absorbance of each plate was read
spectrophotometrically at 590 nm. In order to corroborate the
lack of cytotoxic effects on Bv.2 cells, a MTT assay (Merck KGaA,
Darmstadt, Germany) was performed. Briefly, MTT (5 mg/mL)
was dissolved in PBS and filter sterilized. Then, 100 mL of the
prepared solution was added to each well. This was incubated
until purple precipitate was visible. Subsequently, 100 µL of
DMSO was added to each well and incubated in darkness for
2 h at room temperature. The absorbance was measured at a
wavelength of 595 nm.
Analysis of Nitrites (NO2
−)
Concentrations of NO2
− were measured using the Griess
method (19) at the time defined in cell culture section. Briefly,
nitrites turn into pink color in contact with an acid solution
containing 1% sulfanilamide and 0.1% N-(1-naphthyl)
ethylenediamine (NEDA). The resulting pink colour is
quantified by colorimetry at 540 nm in a microplate reader
(PowerWave, Bioteck, Torino, Italy).A
B
FIGURE 1 | Effect of (SS)-DS-ONJ in the cellular viability in Bv.2 microglial cells. (A) Chemical structures of the sp
2-IGLs (SS)-DS-ONJ, (SR)-DS-ONJ and DSO2-ONJ.
(B) Bv.2 microglial cells were treated for 24 h with (SS)-DS-ONJ (1–10 mM) and viability was determined by crystal violet staining. Colorimetric quantification results
presented as mean ± SEM (n = 5 independent experiments). The fold changes are presented relative to basal values. *p ≤ 0.05 vs the basal values (two-way ANOVA
followed by Bonferroni t-test.)March 2021 | Volume 12 | Article 632132
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Bv.2 microglial cells were seeded on coverslips 24 h before LPS
stimulation and/or (SS)-DS-ONJ in serum-free medium. Then,
cells were washed in PBS, fixed with 4% (w/v) paraformaldehyde
in PBS for 10 min at room temperature, washed in PBS and
permeated with 0.4% (v/v) Triton X-100 in PBS for 20 min.
Blocking in PBS containing 3% (w/v) BSA and 0.1% (v/v) Triton
X-100 for 2 h and the cells were then left overnight in a humid
chamber at 4°C with rabbit anti-p65 NFkB antibody (1:1000) in
blocking buffer (TBS containing 3% (w/v) BSA and 1% (v/v)
Triton X-100). After that, the cells were incubated in the dark for
2 h with anti-rabbit conjugated Alexa 488 antibody (Molecular
Probes, ThermoFisher Scientific, Waltham, MA, USA). The
nucleus were stained with 4,6-diamidino-2-phenylindole
(DAPI) and mounted with Fluoromount G medium.
For immunofluorescence analysis, the retinal explants were
fixed in 4% (w/v) paraformaldehyde for 24 h at 4°C. Then, the
whole retina was washed in TBS containing 0.1% (w/v) BSA and
0.1% (v/v) Triton X-100 (this buffer was used for all subsequent
washes), and blocked and permeated for 2 h in TBS containing
3% (w/v) BSA and 1% (v/v) Triton X-100. Subsequently, the
retinal explants were then incubated overnight in a humid
chamber at 4°C with rabbit anti-GFAP antibody (1:1000) in
the blocking solution. Retinal explants were washed and
incubated for 90 min with anti-rabbit immunoglobulin
antibody conjugated to Alexa 488 (1:2000; Molecular Probes,
Eugene, OR, USA). After washing, retinal explants were
mounted with medium (Fluoromount G) containing DAPI.
Staining was observed and recorded with an inverted laser
confocal microscope Fluoview MPE/FV 1000, Olympus,
MA, USA).
Quantitative Real-Time Polymerase Chain
Reaction (qPCR) Analysis
Total RNA was extracted with Trizol® reagent (Invitrogen,
Madrid, Spain) and reverse transcribed using a SuperScript™
III First-Strand Synthesis System for qPCR following the
manufacturer’s recommendations (Invitrogen). qPCR was
performed with a Corbett Rotor-Gene 6000, Qiagen sequence
detector. Primer-probe sets for mouse Tnfa, Il6, Il1b, Il10, Nlrp3,
Nos2, Arg1 and 18s were purchased from Applied Biosystems.
Western Blot
Proteins were resolved using denaturing SDS-PAGE, and
transferred to PVDF membranes (Bio-Rad). Membranes were
blocked using 5% nonfat dried milk or 3% BSA in 10 mM Tris-
HCl, 150 mM NaCl, pH 7.5 (TBS), and incubated overnight with
several antibodies (1:1000 unless otherwise stated) in 0.05%
Tween-20-TBS. Immunoreactive bands were visualized using
the enhanced chemiluminescence reagent (Bio-Rad).
Statistical Analysis
Western blot quantification was performed using the ImageJ
program. Values in all graphs are presented as means ± SEM.
Statistical tests were performed using the SPSS 21.0 package for
Windows (SPSS Inc. IBM, Armonk, NY, USA). Data wereFrontiers in Immunology | www.frontiersin.org 4analyzed using one-way ANOVA followed by Bonferroni test
or Student paired t-test when comparisons were between any two
groups. Differences were considered significant at p ≤ 0.05.RESULTS
Anti-Inflammatory Effects of (SS)-DS-ONJ
in LPS-Stimulated Bv.2 Microglial Cells
Chemical structures of sp2-IGLs (SS)-DS-ONJ, (SR)-DS-ONJ and
DSO2-ONJ are presented in Figure 1A. First, we tested the
cytotoxicity of (SS)-DS-ONJ (Figure 1B) on microglia Bv.2
cells at various concentrations (Figure 1B; S1A, B). Based
on these results we used 1 and 10 mM concentrations for
subsequent experiments.
For more insight on the effects of (SS)-DS-ONJ in microglia,
Bv.2 cells were stimulated with LPS, a classical M1 stimulus, after
pre-treatment with (SS)-DS-ONJ for 4 h. The LPS stimulation
induced a pro-inflammatory environment similar to that found
in the diabetic environment (6, 9, 20). Classically activated or
M1 immune cells (macrophages and microglial cells), which are
pro-inflammatory and polarized by lipopolysaccharide (LPS),
produce pro-inflammatory cytokines such as interleukin1b, IL6,
and TNFa (21). Bv.2 microglial cells were cultured for 24 h in the
presence or absence of LPS (200 ng/mL) plus (SS)-DS-ONJ (1 or
10 mM) or M2 cytokines (IL4/IL13) in the pre-treatment
regimen. As shown in Figure 2A and S1C, the elevation of
nitrites in the culture medium induced by LPS was significantly
reduced by the pre-treatment with (SS)-DS-ONJ in a dose-
dependent manner. The 10 mM concentration of (SS)-DS-ONJ
showed the highest anti-inflammatory effect, counteracting
LPS-stimulation. Similarly, Nos2 mRNA and iNOS protein
concentrations, which were elevated in LPS-treated Bv.2
microglial cells, significantly decreased in the presence of
(SS)-DS-ONJ (Figures 2B, C). The effects of (SS)-DS-ONJ on
the mRNA levels of pro-inflammatory cytokines in Bv.2
microglial cells were studied. As depicted in Figure 2D,
the significant increases in Tnfa, Il1b and Il6 mRNAs induced
by LPS stimulation were ameliorated by the pre-treatment
with (SS)-DS-ONJ. Supplementary Figure 2 shows that the
effect of IL4+IL13 cytokines evidenced by the decrease of LPS-
induced mRNA levels of TNFa, IL1b, IL6 and Nos2 was
also evident.The Classical Pro-Inflammatory Kinases
Stress-Activated Pathways Are Modulated
by (SS)-DS-ONJ
The classical MAPKs and NFkB-mediated signaling pathways
involved in the inflammatory processes were examined. LPS-
stimulation induced a rapid, and maximal, effect at 30 min in
the phosphorylation of JNK and p38a MAPK, in parallel
with IkB degradation (Figure 3A). Moreover, treatment with
(SS)-DS-ONJ exerted an anti-inflammatory effect by inducing
a decrease in the phosphorylation of JNK, and preventedMarch 2021 | Volume 12 | Article 632132




FIGURE 2 | Protective effects of (SS)-DS-ONJ against LPS-mediated iNOS activation and elevation of mRNA levels of pro-inflammatory cytokines in Bv.2 microglial
cells. Bv.2 microglial cells were treated for 24 h with LPS (200 ng/mL) or LPS plus (SS)-DS-ONJ (1–10 mM). (A) Colorimetric quantification of nitrites was performed.
(B) mRNA of Nos2 was determined by qRT-PCR. (C) Protein extracts were analyzed by Western blot with the corresponding antibodies against iNOS and a-tubulin
as loading control. Representative autoradiograms are shown. Blots were quantified by scanning densitometry and the results are presented as mean ± SEM.
(D) Tnfa, Il1b, and Il6 mRNA values were determined by qRT-PCR. The results are presented as means ± SEM (n = 6 independent experiments). Fold changes are
calculated relative to the basal value. *p ≤ 0.05 vs LPS treatment, †p ≤ 0.05 vs basal value (two-way ANOVA followed by Bonferroni t-test.).Frontiers in Immunology | www.frontiersin.org March 2021 | Volume 12 | Article 6321325
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with (SS)-DS-ONJ promoted significantly higher levels of p38a
MAPK phosphorylation, as compared to LPS stimulus alone
(Figure 3A).
Previous results obtained with the sulfone analogue DSO2-
ONJ indicated that sp2-IGLs induced local conformational
changes in p38a MAPK, leading to its auto-phosphorylation
and activation (9, 14). Pre-treatment with (SS)-DS-ONJ
prevented LPS-mediated nuclear translocation of p65-NF-kB
(Figure 3B).Frontiers in Immunology | www.frontiersin.org 6(SS)-DS-ONJ Reduces the LPS-Induced
Inflammation by Inflammasome Inhibition
in Bv.2 Microglial Cells
Since in LPS-stimulated microglia IL1b is processed via caspase-
1 through the NACHT, LRR and PYD domains-containing
protein 3 (NLRP3) inflammasome complex (22), we analyzed
whether the anti-inflammatory effect of (SS)-DS-ONJ was
dependent on the inflammasome activation.
The mRNA and protein levels of Nlrp3 were markedly increased
after LPS stimulation. Such levels were significantly reduced uponA
B
FIGURE 3 | Effects of (SS)-DS-ONJ in the activation of MAPKs and NFkB-mediated signaling in LPS-stimulated Bv.2 microglial cells. Bv.2 microglial cells were
stimulated with 200 ng/mL LPS in the absence, or presence, of 10 mM (SS)-DS-ONJ for the indicated time periods. (A) Protein extracts were separated by SDS-
PAGE, and analyzed by Western blot with antibodies against phosphorylated (p)-JNK, total JNK, phosphorylated (p)-p38a MAPK, total p38a MAPK, IkBa and a-
tubulin. Representative autoradiograms are shown (n = 7 independent experiments). Blots were quantified with scanning densitometry, and the results are presented
as mean ± SEM. The ratios between the indicated proteins and the fold changes relative to the basal values are shown. *p ≤0.05 vs LPS treatment (two-way ANOVA
followed by Bonferroni t-test). (B) Confocal immunofluorescence assessment of the nuclear translocation of p65-NFkB in Bv.2 microglial cells following stimulation
with LPS in the presence or absence of (SS)-DS-ONJ. Activation of p65-NFkB nuclear translocation was defined by an increase in immunofluorescence of p65-NFkB
(green channel) in the nuclear regions. Nuclear regions of Bv.2 microglial cells were determined by counterstaining nuclear DNA with DAPI (blue channel). White
arrows indicate the p65-NFkB nuclear o cytoplasmic localization.March 2021 | Volume 12 | Article 632132
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accumulation of pro-caspase-1 pro-form (unprocessed form) in
response to (SS)-DS-ONJ in Bv.2 microglial cells.
M2 Anti-Inflammatory Response Is
Promoted by (SS)-DS-ONJ in Bv.2
Microglial Cells
To evaluate this aspect further, we determined mRNA Il10, an
anti-inflammatory cytokine. As shown in Figure 5A, LPS-Frontiers in Immunology | www.frontiersin.org 7stimulation induced a significantly decrease in Il10 mRNA, and
this effect was abolished with (SS)-DS-ONJ treatment. Moreover,
(SS)-DS-ONJ induced an increase in HO-1 protein
concentrations, an anti-oxidant molecule also with anti-
inflammatory effects (Figure 5B).
We evaluated Arginase-1 expression as a marker of M2
phenotype of microglia in Bv.2 microglial cells stimulated with
LPS with or without (SS)-DS-ONJ pretreatment. Figures 5C, D
summarizes the results showing that (SS)-DS-ONJ induced anA B
C
FIGURE 4 | Protective effects of (SS)-DS-ONJ against LPS-mediated inflammasome activation in Bv.2 microglial cells. (A) Nlrp3 mRNA was measured by qRT-PCR.
(B) Protein extracts were analyzed by Western blot, with antibodies against NLRP3; a-tubulin was used as loading control. (C) Protein extracts were analyzed by
Western blot, with antibodies against caspase-1; a-tubulin was used as loading control. Representative autoradiograms are shown (n = 6 independent experiments).
Blots were quantified using scanning densitometry, and the results are presented as means ± SEM. The results are presented as means ± SEM (n = 6 independent
experiments). Fold changes are calculated relative to the basal values. *p ≤ 0.05 vs LPS treatment, †p ≤ 0.05 vs basal values (two-way ANOVA followed by
Bonferroni t-test).March 2021 | Volume 12 | Article 632132
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on its own, or in the presence of LPS.Retinal Gliosis Is Reduced in Retinal
Explants From BB Rats Treated With (SS)-
DS-ONJ
To establish the time-frame in which BB rats exhibit clear pro-
inflammatory parameters associated with DR, we analyzed the
changes in the concentrations of GFAP in a time-course
experiment. GFAP is a marker of gliosis, which is a hallmarkFrontiers in Immunology | www.frontiersin.org 8of neuro-degenerative retinal diseases, including DR (23, 24).
Reactive GFAP is present in the retinas of BB rats at 4 weeks of
age, and continue to increase in the following weeks (Figure 6A).
To quantify the inflammatory environment present during the
early stages of DR, we determined the specific reactive microglia
marker Iba-1. We observed that values were elevated in the
retinas from BB rats at 4 to 6 weeks of age and increased in a
time-dependent manner (Figure 6A).
We used BB rats as an animal model of autoimmune T1DM,
and observed that the expression of reactive gliosis was
detectable in the retinas of rats at 6 weeks of age (Figure 6B).A B
C D
FIGURE 5 | The anti-inflammatory response mediated by HO-1 and IL-10. Bv.2 microglial cells were stimulated with 200 ng/mL LPS in the presence, or absence, of
10 mM (SS)-DS-ONJ for 24 h. (A) Il10 mRNA determined by qRT-PCR. (B) Protein extracts were analyzed by Western blot with antibodies against HO-1 and a-
tubulin (loading control). Representative autoradiograms are shown. Blots were quantified using scanning densitometry. (C) Arg1 mRNA determined by qRT-PCR.
The results are presented as means ± SEM. (D) Protein extracts were analyzed using Western blot, with antibodies against Arginase-1; a-tubulin was a loading
control. Representative autoradiograms are presented. Blots were quantified using scanning densitometry. The results are presented as means ± SEM. Fold changes
are relative to the basal values. *p ≤ 0.05 vs LPS treatment, †p ≤ 0.05 vs the basal values (two-way ANOVA followed by Bonferroni t-test).March 2021 | Volume 12 | Article 632132
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features were maintained in retinal explants. Hence, we prepared
retinal explants from 6 weeks-old rats that were treated with (SS)-
DS-ONJ at 20 mM for 24 h; this dose was judged optimal after
previous dose-response study (data not shown). The analysis of
GFAP expression by immunofluorescence revealed a dramatic
blunting of reactive gliosis in retinal explants treated with (SS)-
DS-ONJ (Figure 6B).Frontiers in Immunology | www.frontiersin.org 9DISCUSSION
Most of the new therapeutic approaches to combat DR are
directed towards the immune system. Indeed, the pro-
inflammatory environment in the course of DR is associated
with altered immune responses (6) in the retina and, therefore,
their modulation offers appealing opportunities to slow DR
progression, and prevent the loss of visual function.A
B
FIGURE 6 | Reactive gliosis is present in BB rats from 6 weeks of age, and treatment with (SS)-DS-ONJ reduced reactive gliosis. (A) Analysis of GFAP and Iba-1 in
retinas from BB rats during DR progression. Protein concentrations in retinal extracts were analyzed by Western blot, with a-tubulin used as loading control.
Representative autoradiograms are shown. Results are presented as means ± SEM (n = 5 retinas per condition). *p ≤ 0.05 BB vs WT matched at each age.
(B) (upper panels) Retinas from 6 weeks old BB and WT rats. (lower panels) Retinal explants from 6 weeks old BB rats were treated for 24 h with (SS)-DS-ONJ
(20 mM) or treatment vehicle alone. Immunostaining for GFAP (green) was performed in whole retinas. Representative images are shown (n = 5 retinas per condition).March 2021 | Volume 12 | Article 632132
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anti-inflammatory activity of the (SS)-DS-ONJ member of sp
2-
IGLs, using an in vitro cellular bioassay that reproduces the pro-
inflammatory environment of DR. In previous studies, we
demonstrated that different sp2-iminosugar glycolipids (25)
elicit beneficial effects due to their anti-inflammatory potential.
The results had revealed that the nature of the glycosidic group
bridging the sugar-like glycone moiety and the lipid aglycone
confers the ability to exert an anti-inflammatory effect by
triggering different signaling pathways in microglia. Of
relevance is that the sulfone DSO2-ONJ elicits anti-
inflammatory effects, probably by favorably orienting the sp2-
IGL molecule in the lipid binding pocket of p38a MAPK (9). In
this regard, we recently demonstrated (9) that the (SR)-
configured sulfoxide (SR)-DS-ONJ attenuates JNK and NFkB
signaling pathways. In this study, we extended the research into
the effects of the related sulfoxide (SS)-DS-ONJ. Here as well, we
found potent anti-inflammatory effects preventing LPS-induced
stress in Bv.2 microglial cells as well as retinal explants from type
1 diabetic BB rats. A further step investigated the molecular
mechanisms involved.
Treatment of Bv.2 microglial cells with a non-toxic
concentration (10 µM) of (SS)-DS-ONJ or IL4/IL13 mixture
reduced NO production and inhibited LPS-induced Nos2 and
pro-inflammatory cytokines mRNA expression. This result
corroborates that (SS)-DS-ONJ presents anti-inflammatory
effects and induces an M2-response similar to those observed for
the classical M2-mediated cytokines stimulus. Importantly, (SS)-
DS-ONJ increased the Il10mRNA, an anti-inflammatory cytokine.
The detailed study of the pro-inflammatory signaling pathways
involved in these effects showed that (SS)-DS-ONJ successfully
inhibited LPS-mediated degradation of IkB, and the translocation
of p65 NFkB to the nucleus, as the analogues sp2-IGL molecules
(DSO2-ONJ and (SR)-DS-ONJ) did. Moreover, (SS)-DS-ONJ
targeted the inflammasome complex by blocking Nlrp3 mRNA
expression. Of note, the accumulation of pro-form caspase-1 by
(SS)-DS-ONJ and the decrease of Nlrp3 mRNA expression and
protein levels could explain the observed inflammasome complex
inhibition. In this regard, the (SS)-DS-ONJ treatment is able to
modulate several key targets in the inflammatory processes, while
driving towards a delayed pro-inflammatory response and
promoting the anti-inflammatory response.
The mechanisms by which immuno-regulatory sp2-IGLs
increase Arginase-1 and IL10 in microglia are, still, only
partially understood. Microglia cells show specific phenotypes
and are modified depending on the activation signals and the
cytokine environment to which they are exposed. The M2
microglial cells phenotype arises in the presence of the anti-
inflammatory cytokine IL10 (26) which could increase Arginase-
1 expression, as detected in our study. By contrast, no changes in
the levels of other anti-inflammatory cytokines expression, such
as IL4 or IL13, were detected upon (SS)-DS-ONJ treatment (data
not shown). The anti-inflammatory cocktail of both IL4 and IL13
cytokines produces a strong protective response against the effect
of LPS; however, our results show that (SS)-DS-ONJ treatment
does not modulate IL4 and/or IL13 expression.Frontiers in Immunology | www.frontiersin.org 10Up-regulation of HO-1, an anti-oxidant molecule, is an
essential cyto-protective mechanism activated in response to
cellular insult. Moreover, HO-1 is able to mediate a robust anti-
inflammatory effect through of inhibition of pro-inflammatory
cytokines production by activated macrophages (27). Conversely,
blocking HO-1 expression reduces the M2 markers IL10 and
Arginase-1 (28). In this study, we demonstrated a direct link
between the induction of HO-1 protein expression and the
increase in Il10 and Arg1 mRNA in Bv.2 microglial cells treated
with (SS)-DS-ONJ. The anti-inflammatory action of (Ss)-DS-ONJ
has been connected to critical nodes of different signaling
pathways involved. We hypothesized that these effects could be
synergistic, concertedly generating a strong anti-inflammatory
response in microglial cells.
Our results are in agreement with the classical cellular
response to an acute insult in which cellular defenses are
activated only in response to a deleterious environment. As
demonstrated in recent studies, HO-1 and IL10 are able to
induce their anti-inflammatory effects in a reciprocal manner
(29). Also, it is important to note that this reciprocal induction is
dependent on p38a MAPK activation (30, 31). We previously
demonstrated that DSO2-ONJ induced p38a MAPK auto-
phosphorylation upon binding to the allosteric lipid binding
site, a conformational structural change. Also, we observed a
similar effect in the presence of (SS)-DS-ONJ. Of note is that both
compounds share the same lipid chain, and differ only in the
oxidation state of the sulfur atom (sulfone and sulfoxide,
respectively; Figure 1A).
As with most diabetic complications, DR is a multifactorial
disease that is linked to inflammation, hyperglycemia and
neuronal dysfunction, as main features in its pathogenesis (32).
T1DM is defined as a chronic, low-grade, systemic, inflammatory
disease characterized by changes in the secretion of cytokines as
well as the polarization of tissue-resident immune cells. Innate
immune microglial-cells in the central nervous system tend
towards the M1 state (33), as demonstrated by the increased
plasma concentrations of pro-inflammatory cytokines (34). The
BB rat is considered a good animal model for DR study because it
mimics human DR progression and, hence, this animal model
has been used to analyze processes such as retinal
neurodegeneration and retinal vascular leakage, as well as to
study potential pharmacological treatment options in preclinical
studies (35, 36). With respect to diabetes-associated retinal
inflammation, a previous study in different animal models
described an increase in inflammatory markers in the retinal
tissue (37, 38). In the present study, we used BB rats to explore
the switching from M1 towards M2 stage during DR in a
systemic pro-inflammatory environment. Our data showed
that GFAP and Iba-1, classic markers of activated microglia
cells, increased in an age-dependent manner in the retina of
diabetic BB rats. Of relevance is that reactive gliosis was
evidenced by increased GFAP expression in BB rats at 6 weeks
of age, with patterns of Mueller cells foot swelling processes (39)
associated with cell death, or apoptosis (40).
Our previous data in retinal explants from db/db mice
demonstrated that treatment with the sulfone sp2-IGL DSO2-ONJMarch 2021 | Volume 12 | Article 632132
Cano-Cano et al. A M2-Response Induction Delay DR Progressionameliorated reactive gliosis (6, 9). Interestingly, reactive gliosis in
retinal explants from BB rats, a T1DM autoimmune animal
model, was also reduced by the treatment with the sulfoxide
analogue (SS)-DS-ONJ, showing a regression towards an early
stage of DR. As reactive gliosis is present in DR (40–42), these
results might have new therapeutic implications such as novel
strategies for targeting DR associated with T1DM or T2DM
based on the specific induction of the M2 response in the retinaFrontiers in Immunology | www.frontiersin.org 11through sp2-IGL-mediated increase in Arginase-1. The
analogues of sp2-IGLs, with specific structural modifications,
share a common anti-inflammatory response mediated by
different signaling cascades. As such, a combination of these
analogues could show synergistic effects in the neuro-
inflammatory context. Similarly, the strong M2 response
induced in diabetic retinal inflammation models offers the
possibility of extrapolating these effects to other retinalFIGURE 7 | Schematic representation of the anti-neuro-inflammatory mechanisms triggered by (SS)-DS-ONJ; 1) The pro-inflammatory environment activates NF-kB
in microglia cells resulting in the transcription of IL-1b; 2) The diabetic status increases the formation of NLRP3 inflammasome, promotes the cleavage of pro-
caspase-1 to its active form and increases IL-1b processing and secretion. The (SS)-DS-ONJ compound could inhibit NF-kB as well as NLRP3; 3) (SS)-DS-ONJ
induces the expression of IL-10, HO-1 and arginase-1 driving a switch of microglia polarization towards the M2 stage to counteract inflammation in microglia cells.March 2021 | Volume 12 | Article 632132
Cano-Cano et al. A M2-Response Induction Delay DR Progressiondegeneration models concurring with neuro-inflammation in the
course of disease progression.i.e. retinitis pigmentosa,
among others.
Our encouraging results suggest that in vivo studies should be
conducted with these chemical compounds to evaluate their
ability to prevent and/or slow the rate of progression of DR.CONCLUSIONS
In summary, the results obtained in this study demonstrate the
anti-inflammatory effect of the (SS)-DS-ONJ compound in
microglial cells and in retinal explants from a classical animal
model of T1DM with DR. As such, the field of sp2-IGL as DR
treatment candidates becomes considerably expanded (Figure
7). (SS)-DS-ONJ treatment upregulates HO-1, IL10 and
Arginase-1 expression in microglial cells, and increases their
anti-inflammatory M2 response. Our study further highlights the
critical involvement of a pro-inflammatory status in DR
progression, and strongly suggests that remodeling M1 towards
an M2 microglia polarization response represents a hopeful
therapeutic option to delay and/or prevent the loss of visual
function associated with DR.DATA AVAILABILITY STATEMENT
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(PI18/01287), Consejerıá de Salud de la Junta de Andalucıá (PI-
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